Pharma News

The FDA has pushed back its decision date for Gamida Cell’s Biologics License Application (BLA) for omidubicel — a drug that treats patients with blood cancer in need of a bone marrow transplan...

Aquatic Therapy Improves MS Fatigue, MS Disease Pathology Not Defined by Courses, Rituximab Shows Positive Effect in Myasthenia Gravis. Welcome to this special edition of Neurology News Network.&nb...

A common chemotherapy drug could carry a toxic inheritance for children and grandchildren of adolescent cancer survivors, Washington State University-led research indicates. ...

The European Commission has provided around €7 million ($7.2 million) in funding to a new project that aims to boost the ability of hospitals within the EU to collect real-world data (RWD) to gau...

The FDA has granted Fast Track designation to Palisade Bio’s investigational drug LB1148 to accelerate the return of bowel function following gastrointestinal surgery. ...

A new bill, the Breakthrough Therapies Act, would encourage the reclassification of MDMA and psilocybin from schedule I to schedule II drugs.

The European Commission (EC) has granted approval for AbbVie’s Skyrizi (risankizumab, 600 mg intravenous induction and 360 mg subcutaneous maintenance therapy) to treat moderately to severely ac...

Today, the U.S. Food and Drug Administration approved Hemgenix (etranacogene dezaparvovec), an adeno-associated virus vector-based gene therapy for the treatment of adults with Hemophilia B (congen...

Building on the CRISPR gene-editing system, MIT researchers have designed a new tool that can snip out faulty genes and replace them with new ones, in a safer and more efficient way. ...

South African bio-pharmaceutical firm Biovac and the International Vaccine Institute (IVI) in South Korea have signed a licencing and technology transfer agreement for developing and manufacturing ...

Zooming in on a single disease and studying it intensely is often the most productive route to finding treatments.

Johnson & Johnson’s Spravato therapy for treatment-resistant depression (TRD) hasn’t made the impact the company hoped for in the market, and it is looking to new clinical results to accele...